Page 80 - Portuguese Journal - SPORL - Vol 61. Nº1

Bibliographic references Lee SE. et al. Efficacy and safety of dupilumab in patients
1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, with severe chronic rhinosinusitis with nasal polyps
Reitsma S. et al. European Position Paper on Rhinosinusitis (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results
and Nasal Polyps 2020 [Internet]. Rhinology. 2020 Feb from two multicentre, randomised, double-blind, placebo-
20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600. Disponível controlled, parallel-group phase 3 trials. Lancet. 2019 Nov
em: https://www.rhinologyjournal.com/Documents/ 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1.
Supplements/supplement_29.pdf 15. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE.
2. Veloso-Teles R, Roque-Farinha R, Buchwald C. Study et al. Efficacy and safety of omalizumab in nasal polyposis:
of the etiopathogenesis of chronic rhinosinusitis with 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020
nasal polyps: focus on the host-environment interaction Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032.
[master's thesis] [Covilhã, Portugal]: Universidade da Beira 16. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson
Interior; 2020. 150 p. Available from: http://hdl.handle. BJ, Gevaert P. et al. Effect of subcutaneous dupilumab on
net/10400.6/10315 nasal polyp burden in patients with chronic sinusitis and
3. Brown WC, Senior B. A Critical look at the efficacy nasal polyposis: a randomized clinical trial. JAMA. 2016 Feb
and costs of biologic therapy for chronic rhinosinusitis 2;315(5):469-79. doi: 10.1001/jama.2015.19330.
with nasal polyposis. Curr Allergy Asthma Rep. 2020 Apr 17. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck
22;20(6):16. doi: 10.1007/s11882-020-00910-y. N, Bauters W. et al. Omalizumab is effective in allergic
4. Cerejeira R, Veloso-teles R, Lousan N, Moura CP. and nonallergic patients with nasal polyps and asthma. J
Prevalence of nasal polyps in Northern Portugal: a cadaver Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1. doi: 10.1016/j.
endoscopic study. Rhinology. 2014 Dec;52(4):386-9. doi: jaci.2012.07.047.
10.4193/Rhino14.016. 18. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van
5. Veloso-teles R, Cerejeira R, Roque-farinha R, Buchwald Zele T, Acke F. et al. Mepolizumab, a humanized anti-IL-5
C Von. Higher prevalence of nasal polyposis among textile mAb, as a treatment option for severe nasal polyposis.
workers: an endoscopic based and controlled study. J Allergy Clin Immunol. 2011 Nov;128(5):989-95.e1-8. doi:
Rhinology. 2018 Jun 1;56(2):99-105. doi: 10.4193/Rhin17.228 10.1016/j.jaci.2011.07.056.
6. Veloso-teles R, Cerejeira R. Endoscopic sinus surgery for 19. Han JK, Bachert C, Fokkens W, Desrosiers M,
chronic rhinosinusitis with nasal polyps: clinical outcome Wagenmann M, Lee SE. et al. Mepolizumab for chronic
and predictive factors of recurrence. Am J Rhinol Allergy. rhinosinusitis with nasal polyps (SYNAPSE): a randomised,
2017 Jan 1;31(1):56-62. doi: 10.2500/ajra.2017.31.4402. double-blind, placebo-controlled, phase 3 trial. Lancet
7. Dalziel K, Hons BHS, Stein K, Round A, Garside R, Royle P. Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-
Endoscopic sinus surgery for the excision of nasal polyps: a 2600(21)00097-7.
systematic review of safety and effectiveness. Am J Rhinol. 20. Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P,
Sep-Oct 2006;20(5):506-19. doi: 10.2500/ajr.2006.20.2923. Nasser S. et al. Reduced need for surgery in severe nasal
8. Willson TJ, Naclerio RM, Lee SE. Monoclonal antibodies polyposis with mepolizumab: Randomized trial. J Allergy
for the treatment of nasal polyps. Immunol Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14. doi: 10.1016/j.
Clin North Am. 2017 May;37(2):357-367. doi: 10.1016/j. jaci.2017.05.044.
iac.2017.01.008. 21. Tversky J, Lane AP, Azar A. Benralizumab effect on
9. Higgins JPT, Altman DG SJ. Chapter 8: Assessing risk severe chronic rhinosinusitis with nasal polyps (CRSwNP):
of bias in included studies. In: Higgins JPT, Churchill R, A randomized double-blind placebo-controlled trial. Clin
Chandler J CM, editor. Cochrane Handbook for Systematic Exp Allergy. 2021 Jun;51(6):836-844. doi: 10.1111/cea.13852.
Reviews of Interventions [Internet]. version 5. 2017. p. 1–73. 22. Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler
Disponível em: https://training.cochrane.org/handbook/ E, Hopkins C. et al. Efficacy and safety of benralizumab in
current/chapter-08 chronic rhinosinusitis with nasal polyps: A randomized,
10. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. placebo-controlled trial. J Allergy Clin Immunol. 2022
Psychometric validity of the 22-item Sinonasal Outcome Apr;149(4):1309-1317.e12. doi: 10.1016/j.jaci.2021.08.030.
Test. Clin Otolaryngol. 2009 Oct;34(5):447-54. doi: 23. FDA. FASENRA® (Benralizumab) Highlights of
10.1111/j.1749-4486.2009.01995.x. Prescribing Information [Internet]. Fda. 2019 [cited 2022
11. Chowdhury NI, Mace JC, Bodner TE, Alt JA, Deconde mar 31]. p. 23. Disponível em: https://www.accessdata.fda.
AS, Levy JM. et al. Investigating the minimal clinically gov/drugsatfda_docs/label/2019/761070s005lbl.pdf
important difference for SNOT-22 symptom domains 24. EMA. Fansera : EPAR - Product Information [Internet].
in surgically managed chronic rhinosinusitis. Int Forum Vol. 16, Netherlands Yearbook of International Law. 1985
Allergy Rhinol. 2017 Dec;7(12):1149-1155. doi: 10.1002/ [cited 2022 mar 31]. p. 51. Disponível em: https://www.ema.
alr.22028. europa.eu/en/documents/product-information/fasenra-
12. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple epar-product-information_en.pdf
BF, Nicklas RA. et al. Rhinosinusitis: developing guidance 25. FDA. DUPIXENT® (Dupilumab) Highlights of
for clinical trials. J Allergy Clin Immunol. 2006 Nov;118(5 Prescribing Information [Internet]. Fda. 2021 [cited 2022
Suppl):S17-61. doi: 10.1016/j.jaci.2006.09.005. mar 31]. p. 47. Disponível em: https://www.accessdata.fda.
13. Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology gov/drugsatfda_docs/label/2021/761055s021s027s033lbl.
[Internet]. 1993;31(4):183–4. Disponível em: https://www. pdf
researchgate.net/publication/15059640_Staging_in_ 26. FDA. XOLAIR® (Omalizumab) Highlights of Prescribing
Rhinosinusitis Information [Internet]. Vol. 50, 2021 [cited 2022 mar 31].
14. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, p. 52. Disponível em: https://www.accessdata.fda.gov/

80 Portuguese Journal of Otorhinolaryngology - Head and Neck Surgery